(Q40546324)

21 September 2017

title

Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model (English)

1 reference

21 September 2017

0 references

metastatic breast cancer

1 reference

1 reference

Margit Maria Janát-Amsbury

1

1 reference

21 September 2017

James W Yockman

2

1 reference

21 September 2017

Minhyung Lee

3

1 reference

21 September 2017

Steven Kern

4

1 reference

21 September 2017

Darin Y Furgeson

5

1 reference

21 September 2017

Malavosklish Bikram

6

1 reference

21 September 2017

Sung Wan Kim

7

1 reference

21 September 2017

publication date

1 June 2004

1 reference

21 September 2017

1 reference

21 September 2017

volume

9

1 reference

21 September 2017

issue

6

1 reference

21 September 2017

page(s)

829-836

1 reference

Breast cancer management: quality-of-life and cost considerations

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Pharmacology and toxicology of Cremophor EL diluent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Hypersensitivity reactions from taxol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

IL-12 deaths: explanation and a puzzle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Development of biomaterials for gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Water-soluble lipopolymer for gene delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMVmIL-12 complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Biodegradable block copolymers for delivery of proteins and water-insoluble drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Camptothecin analogs in malignant gliomas: comparative analysis and characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Interleukin 12: a key modulator of immune function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

The role of gamma interferon in antimicrobial immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Differential tumor surveillance by natural killer (NK) and NKT cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Gene therapy safety issues come to fore

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Enhancement of transgene expression by combining glucocorticoids and anti-mitotic agents during transient transfection using DNA-cationic liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

[Current state of chemosensitivity testing of tumors]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.03.015

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMTHE.2004.03.015

1 reference

21 September 2017

1 reference